Adam Cook represents clients in patent infringement and trade secret actions in district court and inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB). His litigation practice spans a broad range of industries, including pharmaceuticals, biotechnology, electrode manufacturing, robotics, and computer software. He has particular experience in Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) litigations.
Adam has prepared and prosecuted patents in the fields of batteries, metallurgy, plastics manufacturing, chemical plant design, medical devices, artificial intelligence (AI), data processing, cybersecurity, safety devices, ordnance, and food processing, including Patent Cooperation Treaty (PCT) and national patent prosecutions worldwide. He also represents clients in ex parte reexamination proceedings at the U.S. Patent and Trademark Office (USPTO).
Adam participates in the Western District of Pennsylvania’s Pro Se Prisoner Civil Rights Pro Bono Mediation Program, and beyond his client work, he regularly contributes to Jones Day's PTAB Litigation Blog.
经验
其他出版物
- February 18, 2026
An Empirical Dissection of Discretionary Denials Following Bifurcation Policy, 25 Chi.-Kent J. Intell. Prop. 238 (2026) - July 22, 2025
Motions to Amend: Have the Changes Made by the USPTO’s Pilot Program Resulted in More Favorable Outcomes for Patent Owners?, 24 Chi.-Kent J. Intell. Prop. 138 (2025)
- Pennsylvania State University (J.D. summa cum laude 2024; Order of the Coif; Woolsack Honor Society; Comments Editor, Penn State Law Review; B.S. in Chemical Engineering 2021)
- Pennsylvania, U.S. District Court for the Western District of Pennsylvania, and registered to practice before the United States Patent and Trademark Office
发送前请注意
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice